{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069195","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.352832+00:00","generated_at":"2026-05-21T23:51:49.384210+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dianthus Q1 net loss $29.5M; gMG trial enrollment complete, top-line Sep 2025","bullets":["Net loss $29.5M ($0.82/sh) vs $13.7M ($0.54/sh) Q1 2024; cash $331.5M, runway into 2H'27.","Phase 2 MaGic gMG trial enrolled 65 patients; top-line results expected September 2025.","Phase 3 CAPTIVATE CIDP trial ongoing; interim responder analysis 2H'26.","Phase 2 MoMeNtum MMN trial ongoing; top-line results 2H'26.","Appointed John C. King as CCO and Sujay Kango to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069195","json":"https://secwatch.observer/filing/0000950170-25-069195.json","markdown":"https://secwatch.observer/filing/0000950170-25-069195.md","text":"https://secwatch.observer/filing/0000950170-25-069195.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025069195/0000950170-25-069195-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000095017025069195/dnth-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:51:49.384210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}